EDIT

Editas Medicine Inc
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$394.70M
P/E Ratio
—
EPS
$-0.68
Beta
2.08
52W High
$3.94
52W Low
$1.66
50-Day MA
$2.70
200-Day MA
$2.69
Dividend Yield
—
Profit Margin
-157.30%
Forward P/E
—
PEG Ratio
0.00

About Editas Medicine Inc

Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$47.01M
Gross Profit (TTM)$-37.95M
EBITDA$-81.03M
Operating Margin-167.30%
Return on Equity-118.80%
Return on Assets-23.30%
Revenue/Share (TTM)$0.46
Book Value$0.69
Price-to-Book3.73
Price-to-Sales (TTM)8.40
EV/Revenue4.192
EV/EBITDA-1.36
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)232.30%
Shares Outstanding$153.58M
Float$115.43M
% Insiders0.18%
% Institutions80.16%

Historical Volatility

HV 10-Day
103.72%
HV 20-Day
99.12%
HV 30-Day
85.67%
HV 60-Day
82.92%
HV Rank
62.3%

Volatility is currently expanding

Analyst Ratings

Consensus ($6.10 target)
8
Buy
3
Hold
2
Strong Sell

Latest News

Editas Medicine Announces Third Quarter 2026 Results and Business Updates

Company received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia New preclinical data presented at AHA Scientific Sessions demonstrating ≥90 percent LDL-C reduction maintained over 10 months supports EDIT-401's potential best-in-class profile Second IND/CTA accepted for CD70 HD Allo CAR T program as part of collaboration with Bristol Myers Squibb, triggering milestone payment to Editas Cash runway into second half of 2028, through and beyond key clinical readouts from Strive study CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the third quarter 2026 and provided business updates.

GlobeNewsWire11/9/2026Neutral
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany.

GlobeNewsWire10/14/2026Neutral
Editas Medicine Reports Inducement Grants to New Chief Medical Officer

CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company's newly appointed Chief Medical Officer, Daniel Ory, M.D.

GlobeNewsWire9/9/2026Neutral
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401

Editas Medicine NASDAQ: EDIT is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O'Neill said during a Wells Fargo discussion.

MarketBeat9/9/2026Neutral
Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September: Wells Fargo Healthcare Conference Format: Fireside ChatDate: Tuesday, September 8Time: 4:30 p.m.

GlobeNewsWire9/1/2026Neutral
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.

Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 to the clinic Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 to the clinic

GlobeNewsWire8/4/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on EDIT and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 11/9/2026